Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — B. Riley Securities Radiopharma Investor Conference 2024
16 slides from Radiopharm Theranostics's conference presentation, Mar 4, 2024
Slide 1: B. Riley Securities Radiopharma Investor Conference presentation
ASX ANNOUNCEMENT 4 MARCH 2024 B. Riley Securities Radiopharma Investor Conference presentation Sydney, Australia – 4 March 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative radiopharmaceuticals for are
Slide 2: B. Riley Radiopharm Day – March 1st, 2024
For personal use only B. Riley Radiopharm Day – March 1st, 2024 R AD I O P H AR M T H E R AN O S T I C S L T D 2 0 2 4 1
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN
Slide 4: Developing a World-Class Platform of Next-Generation Radiopharmaceutical Products to Fight Cancer
DEVELOPING A WORLD-CLASS PLATFORM OF NEXT-GENERATION RADIOPHARMACEUTICAL PRODUCTS TO FIGHT CANCER Pipeline of Novel Candidates • Two Imaging clinical-stage programs (one completed Phase 2a; one currently in Phase 1 ) For personal use only • One Therapeutic clinical-stage program, currently in Phase
Slide 5: Key Management Team
KEY MANAGEMENT TEAM For personal use only Paul Hopper Riccardo Canevari Vittorio Puppo Dr. Sherin Al-Safadi Vimal Patel Executive Chairman Chief Executive Officer Chief Operating Officer VP, Medical Affairs VP, CMC • Founder of Radiopharm • Radiopharm Theranostics • Has served as Chief • Served in t
Slide 6: Company Pipeline (with Clinical Stage Priorities)
COMPANY PIPELINE (WITH CLINICAL STAGE PRIORITIES ***) RAD CODE TARGET & MOLECULE INDICATION Dx/Tx ISOTOPE PRECLINICAL PHASE I PHASE II NOTES FDA Orphan Drug Designation RAD301 Integrin Imaging Ga68 *** Phase 1* enrolling in the USA For personal use only 1st participant dosed Feb 29th, 2024 αVβ6 PANC
Slide 7: Integrin αVβ6: Imaging and Therapy for Pancreatic Cancer
Integrin αVβ6 : Imaging and Therapy for Pancreatic Cancer TRIVEHEXIN For personal use only RGD peptide (arginylglycylaspartic acid) Integrin αvβ6 receptor antagonist Marker for tumour invasion and metastatic LINKER growth CANCER CELL TARGET Expression correlates with decreased survival in TARGETING
Slide 8: RAD301 Clinical Development: Investigator Initiated Trial
RAD301 Clinical Development: Results Indicate that RAD301 shows incremental Investigator Initiated Trial at value over F18-FDG in PDAC & HNSCC Fortis Medical Center, supported • Favorable tumour-to-background contrast vs F18-FDG by TRIMT • Sharper images and negligible uptake in the surrounding For
Slide 9: Fatty Acid Oxidation: Imaging and Therapy for Brain Metastases
Fatty Acid Oxidation: Imaging and Therapy for Brain Metastases F18-PIVALATE For personal use only Selectively targets fatty acid synthetase which is overexpressed in tumours but not normal brain cells LINKER CANCER CELL TARGET TARGETING RADIOACTIVE Fatty acid MOLECULE ISOTOPE Oxidation 18F to IMAGE
Slide 10: Pivalate Delivers Positive Phase II Data in Brain Metastasis Trial
F18-pivalate PET showed high uptake Pivalate Delivers Positive Phase II RESULTS independent of origin of primary Data in Brain Metastasis Trial tumour Indicates that pivalate can be used to detect & monitor cerebral metastases For personal use only RAD101 Phase IIa Clinical Trial: • Patients without
Slide 11: PD-L1 Nanobody: Combo-Therapy for Lung Cancer
PD-L1 NANOBODY: COMBO-THERAPY FOR LUNG CANCER PD-L1 NANOMAB For personal use only Single domain monoclonal antibody (Sd mAb) PD-L1 Immune Checkpoint Protein Overexpression mediates evasion of immune LINKER responses by cancer cells CANCER CELL Blockade by antibodies leads to tumour TARGET TARGETING
Slide 12: HER Nanobody: Post-ADC Therapy
HER 2 NANOBODY: POST-ADC THERAPY HER 2 NANOMAB Single domain monoclonal antibody (Sd mAb) For personal use only HER 2 pathway proven in Oncology Overexpression in Breast Cancer and LINKER Gastroesophageal cancers CANCER CELL TARGET TARGETING RADIOACTIVE HER2 MOLECULE ISOTOPE 99Tc to SEE Sd mAb 177Lu
Slide 13: From Joint Venture with MD Anderson: First and Only B7-H3 Radiopharmaceutical
FROM JOINT VENTURE WITH MD ANDERSON: FIRST AND ONLY B7-H3 RADIOPHARMACEUTICAL IN DEVELOPMENT For personal use only BETABART® ® Isoform-Selective Targeting of 4Ig-B7-H3 for PET Imaging and Beta-Radioligand Therapy LINKER CANCER CELL TARGET TARGETING RADIOACTIVE B7H3 MOLECULE ISOTOPE 177Lu Betabart TH
Slide 14: Five B7H3 Antibody Drug Conjugates in Development
FIVE B7H3 ANTIBODY DRUG CONJUGATES IN DEVELOPMENT PHASE 2 READOUT WITH B7H3 ADC IN PROSTATE CANCER EXPECTED SOON For personal use only Ph2 TAMARAK B7H3 study in mCRPC Read-out around ASCO 2024 R AD I O P H AR M V E N T U R E S L L C 2 0 2 4 13
Slide 15: Prostate Cancer: First Potential Validation for B7H3
PROSTATE CANCER: FIRST POTENTIAL VALIDATION FOR B7H3: Prostate Cancer management needs for new pathways/targets to improve clinical outcomes, quality of life, and reduce off-tissue toxicities For personal use only Current standard with AT, PARP, PSMA Radioligand NEW Mechanism of Actions B7-H3 ANDROG
Slide 16: Thank You
For personal use only THANK YOU R AD I O P H AR M T H E R AN O S T I C S L T D 2 0 2 4 15
Radiopharm Theranostics — B. Riley Securities Radiopharma Investor Conference 2024 on 6ix